WaveMan
WaveMan · Company
TARS · Tarsus Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

TARS Tarsus Pharmaceuticals (TARS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001819790
Quote by TradingView
Form 144 · 13
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
142
13F, latest reported quarter
Conversions, 180 days
10
Codes C/M, not in net · no price filed

What the filings say about TARS

Insiders, 180 days
-$6.7M net sold
6 sellers · 65% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$21.3M
13 notices

Tarsus Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Tarsus Pharmaceuticals, Inc. insiders sold a net $6.7M of stock across 254 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
LINK WILLIAM J PHD
Director
SELL
2026-09-17 SECtraded 2026-09-15
11,675
$914.5K
-10.3%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Jun 15, 2026.
  • The trade is 12.2% of the 95,312 shares held after it.
  • 3 other insiders sold within 30 days.
  • 142 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director LINK WILLIAM J PHD sold about $914.5K of TARS under a 10b5-1 plan on Sep 15, 2026, the largest insider sale at the company since 2025; 3 other insiders sold within 30 days and 142 funds added in the latest 13F quarter.
LINK WILLIAM J PHD
Director
SELL
2026-09-17 SECtraded 2026-09-15
759
$60.0K
-10.3%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Jun 15, 2026.
  • The trade is 0.8% of the 94,553 shares held after it.
  • 3 other insiders sold within 30 days.
  • 142 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director LINK WILLIAM J PHD sold about $60.0K of TARS under a 10b5-1 plan on Sep 15, 2026; 3 other insiders sold within 30 days and 142 funds added in the latest 13F quarter.
LINK WILLIAM J PHD
Director
SELL
2026-09-17 SECtraded 2026-09-15
66
$5.3K
-10.3%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Jun 15, 2026.
  • The trade is 0.1% of the 94,487 shares held after it.
  • 3 other insiders sold within 30 days.
  • 142 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director LINK WILLIAM J PHD sold about $5.3K of TARS under a 10b5-1 plan on Sep 15, 2026; 3 other insiders sold within 30 days and 142 funds added in the latest 13F quarter.
Lin Elizabeth Yeu
Chief Medical Officer
SELL
2026-09-09 SECtraded 2026-09-04
5,387
$457.9K
-13.7%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (3 buys, 5 sales), the last on Mar 19, 2026.
  • -2.9% median (-2.9% mean) 90-day return after 2 previous buys.
  • The trade is 67.9% of the 7,933 shares held after it.
  • 3 other insiders sold within 30 days.
  • 142 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Lin Elizabeth Yeu sold about $457.9K of TARS under a 10b5-1 plan on Sep 4, 2026; 3 other insiders sold within 30 days and 142 funds added in the latest 13F quarter.
Lin Elizabeth Yeu
Chief Medical Officer
SELL
2026-09-09 SECtraded 2026-09-04
5,386
$484.7K
-13.7%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (3 buys, 5 sales), the last on Mar 19, 2026.
  • -2.9% median (-2.9% mean) 90-day return after 2 previous buys.
  • The trade is 211.5% of the 2,547 shares held after it.
  • 3 other insiders sold within 30 days.
  • 142 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Lin Elizabeth Yeu sold about $484.7K of TARS under a 10b5-1 plan on Sep 4, 2026; 3 other insiders sold within 30 days and 142 funds added in the latest 13F quarter.
254 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 249 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$6.7M over 180 days
-$4.3M over 90 days
below 82% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
142 funds bought in last quarter
more than 80% of Pharma & Biotech
Revenue
+146.7% year over year
more than 87% of Pharma & Biotech
Margin
-14.7% net margin
more than 61% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
18.5% of the float short (float per yahoo 2026-10-26) · 8.3 days to cover · settled 2026-09-30
more than 82% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch TARS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+2.5%12M
-18%-1%+16%+33%2025-102025-122026-022026-042026-062026-082026-10 2026-09-15 · LINK WILLIAM J PHD sold $914.5K2026-06-16 · Farrow Jeffrey S sold $877.4K2026-03-18 · Azamian Bobak R. sold $801.6K2026-03-19 · Azamian Bobak R. sold $801.6K2026-09-02 · Azamian Bobak R. sold $800.6K2026-03-17 · Azamian Bobak R. sold $761.7K2026-01-02 · Whitfield Dianne C. sold $655.5K2026-06-15 · LINK WILLIAM J PHD sold $655.1K2026-03-04 · Neervannan Seshadri sold $641.4K2026-09-04 · Azamian Bobak R. sold $640.9K2025-12-16 · Whitfield Dianne C. sold $592.5K2026-03-16 · LINK WILLIAM J PHD sold $578.3K2025-12-15 · LINK WILLIAM J PHD sold $515.5K2026-09-04 · Lin Elizabeth Yeu sold $484.7K2025-12-15 · LINK WILLIAM J PHD sold $458.4K2026-09-04 · Lin Elizabeth Yeu sold $457.9K2026-01-02 · Whitfield Dianne C. sold $457.7K2025-12-24 · Azamian Bobak R. sold $448.6K2025-12-15 · LINK WILLIAM J PHD sold $407.7K2025-12-15 · LINK WILLIAM J PHD sold $388.4K2026-09-04 · Neervannan Seshadri sold $387.9K2026-06-17 · Azamian Bobak R. sold $334.9K2026-03-19 · Neervannan Seshadri sold $307.5K2026-03-17 · Mottiwala Aziz sold $297.5K2026-03-18 · Mottiwala Aziz sold $297.5K2026-03-19 · Mottiwala Aziz sold $297.5K2026-03-17 · Wahl Bryan sold $283.5K2026-03-19 · Wahl Bryan sold $283.5K2026-03-18 · Wahl Bryan sold $283.4K2026-06-17 · Azamian Bobak R. sold $280.6K2026-03-18 · Whitfield Dianne C. sold $279.7K2026-03-17 · Whitfield Dianne C. sold $279.7K2026-03-19 · Whitfield Dianne C. sold $279.7K2026-09-04 · Azamian Bobak R. sold $264.7K2026-03-18 · Neervannan Seshadri sold $248.0K2026-03-16 · LINK WILLIAM J PHD sold $247.1K2026-03-17 · Neervannan Seshadri sold $216.9K2026-03-20 · Neervannan Seshadri sold $199.5K2026-06-15 · Goodrich Katherine sold $183.4K2025-12-16 · Lin Elizabeth Yeu sold $165.2K2026-03-18 · Farrow Jeffrey S sold $146.6K2026-03-17 · Farrow Jeffrey S sold $146.5K2026-09-15 · WILLIAM J LINK filed to sell $979.7K2026-09-04 · BOBAK AZAMIAN filed to sell $905.6K2026-09-04 · Lin Elizabeth Yeu filed to sell $942.6K2026-09-04 · Lin Elizabeth Yeu filed to sell $278.2K2026-09-04 · Neervannan Seshadri filed to sell $387.9K2026-09-02 · BOBAK AZAMIAN filed to sell $800.6K2026-09-02 · Lin Elizabeth Yeu filed to sell $431.0K2026-09-02 · Lin Elizabeth Yeu filed to sell $127.2K2026-09-02 · Mottiwala Aziz filed to sell $654.4K2026-09-01 · Lin Elizabeth Yeu filed to sell $339.8K2026-09-01 · Mottiwala Aziz filed to sell $5.7M2026-08-25 · Mottiwala Aziz filed to sell $5.8M2026-08-19 · Mottiwala Aziz filed to sell $3.8M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TARS: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
3,856,137 sh
$242.7M
Deep Track Capital, LP
3,666,768 sh
$230.8M
RTW INVESTMENTS, LP
3,357,059 sh
$211.3M
Jupiter Topco LLC
2,808,796 sh
$176.8M
Paradigm Biocapital Advisors LP
2,775,649 sh
$174.7M

Congress trades in TARS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

TARS planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
WILLIAM J LINK
Filed 2026-09-15
$979.7K
BOBAK AZAMIAN
Filed 2026-09-04
$905.6K
Lin Elizabeth Yeu
Filed 2026-09-04
$942.6K
Lin Elizabeth Yeu
Filed 2026-09-04
$278.2K
Neervannan Seshadri
Filed 2026-09-04
$387.9K

TARS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Pharmaceuticals ETF
$11.9M position · as of 2026-07-31
2.5%
Nomura Small Cap Growth Fund
$21.5M position · as of 2026-06-30
1.8%
SFT Nomura Small Cap Growth Fund
$3.6M position · as of 2026-06-30
1.8%
Nomura VIP Small Cap Growth Series
$4.2M position · as of 2026-06-30
1.8%
ALPS Medical Breakthroughs ETF
$2.6M position · as of 2026-05-31
1.6%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$6.7M position · as of 2026-06-30
1.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
12 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
0 active
7
Phase 2
3 active
1
Phase 3
0 active
1
Phase 4
0 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Bobak Azamian
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.6M
$31.1M
$2.7M
+264%
+25%
2024
$7.9M
$19.8M
$3.2M
+146%
-7%
2023
$3.1M
$4.5M
$2.6M
-10%
-6%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $6.7M sold by insiders over 180 days, 142 funds added last quarter, $21.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

TARS financials

Revenue growth
+146.7%
XBRL, annual
Net margin
-14.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$606.3M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-7.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$56.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.21x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
1.02x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-13.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-8.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-11.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$2.9B
market value at close 2026-10-26 on 2026-07-30 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
+1.8%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$451.4M$183.0M$17.4M$25.8M
Operating income-$71.0M-$120.6M-$143.2M-$62.7M
Net income-$66.0M-$116.0M-$136.0M-$62.1M
EPS (diluted)-1.59-3.07-4.62-2.52
Operating cash flow-$12.5M-$83.0M-$117.5M-$49.0M
Cash$183.6M$94.8M$224.9M$71.7M
Long-term debt$72.4M$71.8M$29.8M$19.4M
SEC XBRL, fiscal years, as known on 2026-10-28

TARS Stock Sonar score 6/7 axes

Find similar shapesCompare

TARS ranks highest on growth (87th percentile) and profitability (76th), and lowest on insider conviction (13th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
76
Inputs
  • Return on equity-13.6% · 75 pct, sector of 545
  • Return on assets-8.3% · 76 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-11.6% · 78 pct, sector of 576
Financial health
68
Inputs
  • Debt to equity0.21x · 44 pct, sector of 352
  • Cash flow to debt1.02x · 92 pct, sector of 371
Growth
87
Inputs
  • Revenue growth, YoY+146.7% · 87 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
13
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2.5M · 26 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
61
Inputs
  • Funds adding, latest quarter142 · 80 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$200K · 41 pct, sector of 133
Risk and compliance
46
Inputs
  • Short interest, % of float+18.5% · 18 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+6.6% · 75 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

TARS filings, in plain words

Are Tarsus Pharmaceuticals insiders buying or selling TARS?

In the 180 days to 2026-10-28, Tarsus Pharmaceuticals insiders were net sellers, a net $6.7M across purchases and sales reported on Form 4, by 6 sellers.

Are there planned insider sales of TARS?

Yes. 13 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $21.3M of stock; the latest, by WILLIAM J LINK, was filed 2026-09-15.

Read the full summary

In the 180 days to 2026-10-28, Tarsus Pharmaceuticals insiders were net sellers of TARS, a net $6.7M across purchases and sales reported on Form 4 by 6 sellers. 65% of the 17 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 13 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $21.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies